J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating
Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Express News | Neurocrine Biosciences Inc - Data Consistent Across All Patient Subgroups in Cahtalyst Study
Express News | Neurocrine Biosciences Announces New Results From Exploratory Analyses of the Phase 3 Cahtalyst™ Pediatric Study Demonstrating Crenessity™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups
Neurocrine Biosciences Insider Sold Shares Worth $3,305,952, According to a Recent SEC Filing
New Analyst Forecast: $NBIX Given 'Outperform' Rating
